retatrutide glp-1 gip glucagon agonist Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research The novel GIP, GLP‐1 and

Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular diseaseresults from EMPA-REG OUTCOME

53% achieved a weight reduction of 15%, compared with 5% in the placebo group

With GLP-1 therapy, a supportive diet and exercise regimen, and the insight from DEXA scans, you can lose weight confidently knowing youre preserving your strength and metabolism

No lot number verification

"Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism

Potential benefits: Research shows that tirzepatide leads to greater weight loss than semaglutidelikely because the two hormone mimickers work together for greater effects